Skip to main content

Table 4 Change in NPI from baseline (FAS-LOCF) a

From: Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

 

Group

n

Mean ± SE b

Difference from placebo group b (95% CI)

P- value

NPI-2

Placebo

44

−2.1 ± 0.6

5 mg

45

−1.8 ± 0.6

0.4 (−1.3, 2.0)

0.661

10 mg

49

−2.8 ± 0.5

−0.7 (−2.3, 0.9)

0.391

NPI-10

Placebo

44

−6.4 ± 1.5

5 mg

45

−3.3 ± 1.4

3.0 (−1.0, 7.1)

0.143

10 mg

49

−5.5 ± 1.4

0.9 (−3.1, 4.9)

0.660

  1. aFAS, Full analysis set; LOCF, Last observation carried forward; NPI, Neuropsychiatric Inventory. bLeast squares mean from analysis of covariance with treatment groups as factors and baseline values as covariates. A negative value of the NPI change indicates an improvement in behavioral and neuropsychiatric symptoms.